APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acute Myeloid Leukaemia Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Acute Myeloid Leukaemia Therapeutics Market Analysis and Forecast 2026-2032

4 March 2026193 pages

Choose your research edition.

Industry ResearchAcute Myeloid Leukaemia Therapeutics Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Myeloid Leukaemia Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Acute Myeloid Leukaemia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Myeloid Leukaemia Therapeutics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Myeloid Leukaemia Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Acute Myeloid Leukaemia Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Acute Myeloid Leukaemia Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Acute Myeloid Leukaemia Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Acute Myeloid Leukaemia Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Acute Myeloid Leukaemia Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Acute Myeloid Leukaemia Therapeutics include Pfizer Inc., Novartis AG, Celgene Corporation, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals, Boehringer Ingelheim International GmbH, Johnson & Johnson and Gilead Sciences, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Acute Myeloid Leukaemia Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Acute Myeloid Leukaemia Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Acute Myeloid Leukaemia Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Acute Myeloid Leukaemia Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Acute Myeloid Leukaemia Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Acute Myeloid Leukaemia Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Acute Myeloid Leukaemia Therapeutics Segment by Company

Pfizer Inc.

Novartis AG

Celgene Corporation

Astellas Pharma Inc.

Daiichi Sankyo Company, Limited

Jazz Pharmaceuticals

Boehringer Ingelheim International GmbH

Johnson & Johnson

Gilead Sciences, Inc.

Amgen Inc.

Takeda Pharmaceutical Company Limited

Sunesis Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Acute Myeloid Leukaemia Therapeutics Segment by Type

Chemotherapy

Targeted Therapy

Immunotherapy

Hypomethylating Agents

Others

Acute Myeloid Leukaemia Therapeutics Segment by Application

Specialty Clinics

Hospital

Others

Acute Myeloid Leukaemia Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Myeloid Leukaemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Myeloid Leukaemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Myeloid Leukaemia Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Acute Myeloid Leukaemia Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Acute Myeloid Leukaemia Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acute Myeloid Leukaemia Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Chemotherapy Major Player Table 3. Targeted Therapy Major Player Table 4. Immunotherapy Major Player Table 5. Hypomethylating Agents Major Player Table 6. Others Major Player Table 7. Global Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Specialty Clinics Major Player Table 9. Hospital Major Player Table 10. Others Major Player Table 11. Acute Myeloid Leukaemia Therapeutics Industry Trends Table 12. Acute Myeloid Leukaemia Therapeutics Industry Drivers Table 13. Acute Myeloid Leukaemia Therapeutics Industry Opportunities and Challenges Table 14. Acute Myeloid Leukaemia Therapeutics Industry Restraints Table 15. Global Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Acute Myeloid Leukaemia Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Acute Myeloid Leukaemia Therapeutics Market Share by Region (2021-2026) Table 18. Global Acute Myeloid Leukaemia Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Acute Myeloid Leukaemia Therapeutics Market Share by Region (2027-2032) Table 20. Global Acute Myeloid Leukaemia Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Players (2021-2026) Table 22. Global Acute Myeloid Leukaemia Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Acute Myeloid Leukaemia Therapeutics Key Players Headquarters & Area Served Table 24. Global Acute Myeloid Leukaemia Therapeutics Players, Product Type & Application Table 25. Global Acute Myeloid Leukaemia Therapeutics Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Acute Myeloid Leukaemia Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Acute Myeloid Leukaemia Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Acute Myeloid Leukaemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Type (2021-2026) Table 32. Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Type (2027-2032) Table 33. Global Acute Myeloid Leukaemia Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Acute Myeloid Leukaemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Application (2021-2026) Table 37. Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Application (2027-2032) Table 38. Pfizer Inc. Company Information Table 39. Pfizer Inc. Business Overview Table 40. Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 42. Pfizer Inc. Recent Development Table 43. Novartis AG Company Information Table 44. Novartis AG Business Overview Table 45. Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Novartis AG Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 47. Novartis AG Recent Development Table 48. Celgene Corporation Company Information Table 49. Celgene Corporation Business Overview Table 50. Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 52. Celgene Corporation Recent Development Table 53. Astellas Pharma Inc. Company Information Table 54. Astellas Pharma Inc. Business Overview Table 55. Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 57. Astellas Pharma Inc. Recent Development Table 58. Daiichi Sankyo Company, Limited Company Information Table 59. Daiichi Sankyo Company, Limited Business Overview Table 60. Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 62. Daiichi Sankyo Company, Limited Recent Development Table 63. Jazz Pharmaceuticals Company Information Table 64. Jazz Pharmaceuticals Business Overview Table 65. Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 67. Jazz Pharmaceuticals Recent Development Table 68. Boehringer Ingelheim International GmbH Company Information Table 69. Boehringer Ingelheim International GmbH Business Overview Table 70. Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 72. Boehringer Ingelheim International GmbH Recent Development Table 73. Johnson & Johnson Company Information Table 74. Johnson & Johnson Business Overview Table 75. Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 77. Johnson & Johnson Recent Development Table 78. Gilead Sciences, Inc. Company Information Table 79. Gilead Sciences, Inc. Business Overview Table 80. Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 82. Gilead Sciences, Inc. Recent Development Table 83. Amgen Inc. Company Information Table 84. Amgen Inc. Business Overview Table 85. Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 87. Amgen Inc. Recent Development Table 88. Takeda Pharmaceutical Company Limited Company Information Table 89. Takeda Pharmaceutical Company Limited Business Overview Table 90. Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 92. Takeda Pharmaceutical Company Limited Recent Development Table 93. Sunesis Pharmaceuticals, Inc. Company Information Table 94. Sunesis Pharmaceuticals, Inc. Business Overview Table 95. Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 97. Sunesis Pharmaceuticals, Inc. Recent Development Table 98. Agios Pharmaceuticals, Inc. Company Information Table 99. Agios Pharmaceuticals, Inc. Business Overview Table 100. Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 102. Agios Pharmaceuticals, Inc. Recent Development Table 103. North America Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 104. North America Acute Myeloid Leukaemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 105. North America Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 106. North America Acute Myeloid Leukaemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 107. North America Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. North America Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 109. North America Acute Myeloid Leukaemia Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 110. Europe Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 111. Europe Acute Myeloid Leukaemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 112. Europe Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 113. Europe Acute Myeloid Leukaemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 114. Europe Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Europe Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Acute Myeloid Leukaemia Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 117. China Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 118. China Acute Myeloid Leukaemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 119. China Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 120. China Acute Myeloid Leukaemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 121. Asia Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 122. Asia Acute Myeloid Leukaemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 123. Asia Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 124. Asia Acute Myeloid Leukaemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 125. Asia Acute Myeloid Leukaemia Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Asia Acute Myeloid Leukaemia Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 127. Asia Acute Myeloid Leukaemia Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 128. SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 129. SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 130. SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 131. SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 132. SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 134. SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Acute Myeloid Leukaemia Therapeutics Image Figure 2. Global Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Myeloid Leukaemia Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Chemotherapy Image Figure 5. Targeted Therapy Image Figure 6. Immunotherapy Image Figure 7. Hypomethylating Agents Image Figure 8. Others Image Figure 9. Global Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Acute Myeloid Leukaemia Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 11. Specialty Clinics Image Figure 12. Hospital Image Figure 13. Others Image Figure 14. Global Acute Myeloid Leukaemia Therapeutics Market Size (US$ Million) & (2021-2032) Figure 15. Global Acute Myeloid Leukaemia Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Acute Myeloid Leukaemia Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Acute Myeloid Leukaemia Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Type (2021-2032) Figure 22. Global Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Application (2021-2032) Figure 25. North America Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Acute Myeloid Leukaemia Therapeutics Revenue Share by Type (2021-2032) Figure 27. North America Acute Myeloid Leukaemia Therapeutics Revenue Share by Application (2021-2032) Figure 28. North America Acute Myeloid Leukaemia Therapeutics Revenue Share by Country (2021-2032) Figure 29. United States Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Acute Myeloid Leukaemia Therapeutics Revenue Share by Type (2021-2032) Figure 34. Europe Acute Myeloid Leukaemia Therapeutics Revenue Share by Application (2021-2032) Figure 35. Europe Acute Myeloid Leukaemia Therapeutics Revenue Share by Country (2021-2032) Figure 36. Germany Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Acute Myeloid Leukaemia Therapeutics Revenue Share by Type (2021-2032) Figure 46. China Acute Myeloid Leukaemia Therapeutics Revenue Share by Application (2021-2032) Figure 47. Asia Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Acute Myeloid Leukaemia Therapeutics Revenue Share by Type (2021-2032) Figure 49. Asia Acute Myeloid Leukaemia Therapeutics Revenue Share by Application (2021-2032) Figure 50. Asia Acute Myeloid Leukaemia Therapeutics Revenue Share by Region (2021-2032) Figure 51. Japan Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Acute Myeloid Leukaemia Therapeutics Revenue Share by Type (2021-2032) Figure 59. SAMEA Acute Myeloid Leukaemia Therapeutics Revenue Share by Application (2021-2032) Figure 60. SAMEA Acute Myeloid Leukaemia Therapeutics Revenue Share by Country (2021-2032) Figure 61. Brazil Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Acute Myeloid Leukaemia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hypomethylating Agents
  • Others
Applications
  • Specialty Clinics
  • Hospital
  • Others
Companies covered
  • Pfizer Inc.
  • Novartis AG
  • Celgene Corporation
  • Astellas Pharma Inc.
  • Daiichi Sankyo Company, Limited
  • Jazz Pharmaceuticals
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Sunesis Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Acute Myeloid Leukaemia Therapeutics Market by Type
  3. 1.2.1 Global Acute Myeloid Leukaemia Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Chemotherapy
  5. 1.2.3 Targeted Therapy
  6. 1.2.4 Immunotherapy
  7. 1.2.5 Hypomethylating Agents
  8. 1.2.6 Others
  9. 1.3 Acute Myeloid Leukaemia Therapeutics Market by Application
  10. 1.3.1 Global Acute Myeloid Leukaemia Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Specialty Clinics
  12. 1.3.3 Hospital
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Acute Myeloid Leukaemia Therapeutics Market Dynamics
  1. 2.1 Acute Myeloid Leukaemia Therapeutics Industry Trends
  2. 2.2 Acute Myeloid Leukaemia Therapeutics Industry Drivers
  3. 2.3 Acute Myeloid Leukaemia Therapeutics Industry Opportunities and Challenges
  4. 2.4 Acute Myeloid Leukaemia Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Acute Myeloid Leukaemia Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Acute Myeloid Leukaemia Therapeutics Growth Trends by Region
  3. 3.2.1 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Acute Myeloid Leukaemia Therapeutics Revenue by Players
  2. 4.1.1 Global Acute Myeloid Leukaemia Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Acute Myeloid Leukaemia Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Acute Myeloid Leukaemia Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Acute Myeloid Leukaemia Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Acute Myeloid Leukaemia Therapeutics Players, Product Type & Application
  8. 4.5 Global Acute Myeloid Leukaemia Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Acute Myeloid Leukaemia Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Acute Myeloid Leukaemia Therapeutics Tier 1, Tier 2, and Tier 3
5 Acute Myeloid Leukaemia Therapeutics Market Size by Type
  1. 5.1 Global Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Type (2021-2032)
6 Acute Myeloid Leukaemia Therapeutics Market Size by Application
  1. 6.1 Global Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Pfizer Inc.
  2. 7.1.1 Pfizer Inc. Company Information
  3. 7.1.2 Pfizer Inc. Business Overview
  4. 7.1.3 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  6. 7.1.5 Pfizer Inc. Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG Acute Myeloid Leukaemia Therapeutics Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Celgene Corporation
  14. 7.3.1 Celgene Corporation Company Information
  15. 7.3.2 Celgene Corporation Business Overview
  16. 7.3.3 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product Portfolio
  18. 7.3.5 Celgene Corporation Recent Developments
  19. 7.4 Astellas Pharma Inc.
  20. 7.4.1 Astellas Pharma Inc. Company Information
  21. 7.4.2 Astellas Pharma Inc. Business Overview
  22. 7.4.3 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  24. 7.4.5 Astellas Pharma Inc. Recent Developments
  25. 7.5 Daiichi Sankyo Company, Limited
  26. 7.5.1 Daiichi Sankyo Company, Limited Company Information
  27. 7.5.2 Daiichi Sankyo Company, Limited Business Overview
  28. 7.5.3 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio
  30. 7.5.5 Daiichi Sankyo Company, Limited Recent Developments
  31. 7.6 Jazz Pharmaceuticals
  32. 7.6.1 Jazz Pharmaceuticals Company Information
  33. 7.6.2 Jazz Pharmaceuticals Business Overview
  34. 7.6.3 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product Portfolio
  36. 7.6.5 Jazz Pharmaceuticals Recent Developments
  37. 7.7 Boehringer Ingelheim International GmbH
  38. 7.7.1 Boehringer Ingelheim International GmbH Company Information
  39. 7.7.2 Boehringer Ingelheim International GmbH Business Overview
  40. 7.7.3 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product Portfolio
  42. 7.7.5 Boehringer Ingelheim International GmbH Recent Developments
  43. 7.8 Johnson & Johnson
  44. 7.8.1 Johnson & Johnson Company Information
  45. 7.8.2 Johnson & Johnson Business Overview
  46. 7.8.3 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product Portfolio
  48. 7.8.5 Johnson & Johnson Recent Developments
  49. 7.9 Gilead Sciences, Inc.
  50. 7.9.1 Gilead Sciences, Inc. Company Information
  51. 7.9.2 Gilead Sciences, Inc. Business Overview
  52. 7.9.3 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  54. 7.9.5 Gilead Sciences, Inc. Recent Developments
  55. 7.10 Amgen Inc.
  56. 7.10.1 Amgen Inc. Company Information
  57. 7.10.2 Amgen Inc. Business Overview
  58. 7.10.3 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  60. 7.10.5 Amgen Inc. Recent Developments
  61. 7.11 Takeda Pharmaceutical Company Limited
  62. 7.11.1 Takeda Pharmaceutical Company Limited Company Information
  63. 7.11.2 Takeda Pharmaceutical Company Limited Business Overview
  64. 7.11.3 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio
  66. 7.11.5 Takeda Pharmaceutical Company Limited Recent Developments
  67. 7.12 Sunesis Pharmaceuticals, Inc.
  68. 7.12.1 Sunesis Pharmaceuticals, Inc. Company Information
  69. 7.12.2 Sunesis Pharmaceuticals, Inc. Business Overview
  70. 7.12.3 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  72. 7.12.5 Sunesis Pharmaceuticals, Inc. Recent Developments
  73. 7.13 Agios Pharmaceuticals, Inc.
  74. 7.13.1 Agios Pharmaceuticals, Inc. Company Information
  75. 7.13.2 Agios Pharmaceuticals, Inc. Business Overview
  76. 7.13.3 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  78. 7.13.5 Agios Pharmaceuticals, Inc. Recent Developments
8 North America
  1. 8.1 North America Acute Myeloid Leukaemia Therapeutics Revenue (2021-2032)
  2. 8.2 North America Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Acute Myeloid Leukaemia Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Acute Myeloid Leukaemia Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Acute Myeloid Leukaemia Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Acute Myeloid Leukaemia Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Acute Myeloid Leukaemia Therapeutics Revenue by Country
  11. 8.6.1 North America Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Acute Myeloid Leukaemia Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Acute Myeloid Leukaemia Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Acute Myeloid Leukaemia Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Acute Myeloid Leukaemia Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Acute Myeloid Leukaemia Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Acute Myeloid Leukaemia Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Acute Myeloid Leukaemia Therapeutics Revenue by Country
  11. 9.6.1 Europe Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Acute Myeloid Leukaemia Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Acute Myeloid Leukaemia Therapeutics Revenue (2021-2032)
  2. 10.2 China Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Acute Myeloid Leukaemia Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Acute Myeloid Leukaemia Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Acute Myeloid Leukaemia Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Acute Myeloid Leukaemia Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Acute Myeloid Leukaemia Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Acute Myeloid Leukaemia Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Acute Myeloid Leukaemia Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Acute Myeloid Leukaemia Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Acute Myeloid Leukaemia Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Acute Myeloid Leukaemia Therapeutics Revenue by Country
  11. 11.6.1 Asia Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Acute Myeloid Leukaemia Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Acute Myeloid Leukaemia Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst